245 related articles for article (PubMed ID: 18412349)
1. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
Altman MD; Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Chellappan S; Kairys V; Fernandes MX; Gilson MK; Schiffer CA; Rana TM; Tidor B
J Am Chem Soc; 2008 May; 130(19):6099-113. PubMed ID: 18412349
[TBL] [Abstract][Full Text] [Related]
2. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
3. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
Nalam MN; Ali A; Altman MD; Reddy GS; Chellappan S; Kairys V; Ozen A; Cao H; Gilson MK; Tidor B; Rana TM; Schiffer CA
J Virol; 2010 May; 84(10):5368-78. PubMed ID: 20237088
[TBL] [Abstract][Full Text] [Related]
5. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
7. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
8. Enamino-oxindole HIV protease inhibitors.
Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
[TBL] [Abstract][Full Text] [Related]
9. Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.
Weber IT; Waltman MJ; Mustyakimov M; Blakeley MP; Keen DA; Ghosh AK; Langan P; Kovalevsky AY
J Med Chem; 2013 Jul; 56(13):5631-5. PubMed ID: 23772563
[TBL] [Abstract][Full Text] [Related]
10. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
11. Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Agniswamy J; Shen CH; Wang YF; Ghosh AK; Rao KV; Xu CX; Sayer JM; Louis JM; Weber IT
J Med Chem; 2013 May; 56(10):4017-27. PubMed ID: 23590295
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.
Parai MK; Huggins DJ; Cao H; Nalam MN; Ali A; Schiffer CA; Tidor B; Rana TM
J Med Chem; 2012 Jul; 55(14):6328-41. PubMed ID: 22708897
[TBL] [Abstract][Full Text] [Related]
14. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.
Nalam MN; Ali A; Reddy GS; Cao H; Anjum SG; Altman MD; Yilmaz NK; Tidor B; Rana TM; Schiffer CA
Chem Biol; 2013 Sep; 20(9):1116-24. PubMed ID: 24012370
[TBL] [Abstract][Full Text] [Related]
15. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
Cai Y; Schiffer C
Methods Mol Biol; 2012; 819():551-60. PubMed ID: 22183557
[TBL] [Abstract][Full Text] [Related]
16. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
17. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
[No Abstract] [Full Text] [Related]
18. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Tie Y; Wang YF; Boross PI; Chiu TY; Ghosh AK; Tozser J; Louis JM; Harrison RW; Weber IT
Protein Sci; 2012 Mar; 21(3):339-50. PubMed ID: 22238126
[TBL] [Abstract][Full Text] [Related]
19. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
[TBL] [Abstract][Full Text] [Related]
20. Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
Ghosh AK; Chapsal BD; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2012 Mar; 22(6):2308-11. PubMed ID: 22364812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]